European Union regulators recommended approval of a once-a-day anti-HIV cocktail called Genvoya. This new version of the drug is gentler on a patient’s bones and soft tissues. Genvoya combines elvitegravil, cobicistat, emtricitabine and tenefovir alafenamide.
This drug can be used to treat adults and adolescents 12 years of age and older with a body mass of at least 35 kg who have HIV-1 without any known mutations associated with resistance to emtricitabine. This new drug for HIV-1 is one great achievement in the medical field.
REFERENCES: EUROPEAN MEDICINES AGENCY.
